Evotec and Sernova Announce Exclusive Strategic Partnership for iPSC-based Beta Cell Replacement Therapy to Advance a 'Functional Cure' for Diabetes

Author's Avatar
May 17, 2022
  • PARTNERSHIP LEVERAGES IPSC-BASED BETA CELLS FROM EVOTEC'S QRBETA INITIATIVE COMBINED WITH SERNOVA'S PROPRIETARY IMPLANTABLE CELL POUCH™ DEVICE
  • THE GOAL IS THE DEVELOPMENT AND COMMERCIALISATION OF AN OFF-THE-SHELF BETA CELL REPLACEMENT THERAPY FOR INSULIN-DEPENDENT DIABETES
  • EVOTEC MAKES STRATEGIC € 20 M EQUITY INVESTMENT IN SERNOVA
  • EVOTEC/SERNOVA JOINT CONFERENCE CALL AND WEBCAST AT 8.30 AM EDT MAY 17, 2022